𝔖 Bobbio Scriptorium

✦ LIBER ✦

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

✍ Scribed by Nachega, Jean; Rosenkranz, ; Pham,

Book ID: 118046401
Publisher: Dove Press Ltd.
Year: 2011
Tongue: English
Weight: 174 KB
Category: Article
ISSN: 1177-889X
DOI: 10.2147/ppa.s27558

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-daily dolutegravir versus twice-dai

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

✍ Raffi, François; Jaeger, Hans; Quiros-Roldan, Eugenia; Albrecht, Helmut; Belonos 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 274 KB

Once-daily atazanavir/ritonavir versus t

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

✍ Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetcho 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 246 KB